Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Resmetirom (Rezdiffra) (resmetirom) | Accelerate Your Fibrosis Research

Home/Drugs/Resmetirom (Rezdiffra)

Resmetirom (Rezdiffra)

resmetirom

Approved

Sponsor: Madrigal Pharmaceuticals

Indication: MASH

Mechanism of Action

Thyroid hormone receptor beta (THR-β) selective agonist

Target: THR-β

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT03413124

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

Phase:PHASE1Org:Madrigal Pharmaceuticals, Inc.

COMPLETEDNCT03220165

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

Phase:PHASE1Org:Madrigal Pharmaceuticals, Inc.

COMPLETEDNCT01367873

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Phase:PHASE1Org:Madrigal Pharmaceuticals, Inc.

ACTIVE_NOT_RECRUITINGNCT07335601

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Phase:PHASE2Org:Madrigal Pharmaceuticals, Inc.

COMPLETEDNCT04197479

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Phase:PHASE3Org:Madrigal Pharmaceuticals, Inc.

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.

Alzaki AA, Alqahtani MZ, Aman E et al.

Cureus2026 Mar

Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model.

Honda A, Kamata S, Tanaka R et al.

Biomed Pharmacother2026 Apr 27

[Amendment "Resmetirom" to the S2k guideline "Metabolic Liver Diseases" (formerly "Non-Alcoholic Fatty Liver Disease" v.2.0/April 2022) of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) (Version 2.3)].

Roeb E, Canbay A, Bantel H et al.

Z Gastroenterol2026 Apr

Deciphering cytochrome P450 reductase role in MASLD: molecular mechanisms and pathophysiological implications.

Baptista C, Esteves F, Fallowfield JA et al.

Nat Rev Gastroenterol Hepatol2026 Apr 20

Cost-Effectiveness of Blood-Based Fibrosis Screening in High-Risk Metabolic Liver Diseases With Emerging Therapies.

Chen W, Chang ST, Cheung RC et al.

Gastro Hep Adv2026

View more on PubMed

Validated Models

This drug has been validated in the following preclinical models: